_edited.png){kind=small}
Laboratory of Translational Immuno-Oncology
Laboratory of Translational Immuno-Oncology (중개 면역 항암 연구실)는 다양한 암종에서의 항종양면역반응 회피 기전 규명, 치료 타겟 및 바이오마커 발굴 및 새로운 치료 전략개발을 목표로 하는 중개연구를 수행하고 있습니다.
임상 검체를 바탕으로 한 중개연구를 면역학적인 측면 뿐만 아니라 유전체적인 측면까지 고려하여 면역항암치료의 효과를 개선하는 것이 궁극적인 목표입니다. 임상 검체를 이용하여 multicolor flowcytometry, functional asay single cell RNA sequencing, whole genome sequencing을 기반으로 고전적인 CD8 T 세포 항종양 면역반응 뿐만 아니라, 여러 다양한 면역세포 및 면역-유전체적인 기전을 연구하고자 합니다.
대표 논문
- Kim HD et al. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma. Gastroenterology. 2018 Dec;155(6):1936-1950.
- Kim HD et al. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8+ T cells in Hepatocellular Carcinoma. Hepatology. 2020 Mar;71(3):955-971.
- Kim HD et al. Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer Cancer Res Treat. 2021 Jan;53(1):162-171.
- Kim HD et al. Implication of CD69+CD103+ Tissue-resident-like CD8+ T cells as a Potential Immunotherapeutic Target for Cholangiocarcinoma Liver Int. 2021 Apr;41(4):764-776.
- Jeong S et al. Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade J Immunother Cancer. 2021 Jul;9(7):e002428.
- Kim HD et al. Insertion-Deletion Rate is a Qualitative Aspect of the Tumor Mutation Burden Associated with the Clinical Outcomes of Gastric Cancer Patients Treated with Nivolumab. Gastric Cancer. 2021
Contact
I'm always looking for new and exciting opportunities. Let's connect.
02-3010-0236